IFRX Stock Risk & Deep Value Analysis

InflaRx NV

Healthcare • Biotechnology

DVR Score

4.0

out of 10

Proceed with Caution

What You Need to Know About IFRX Stock

We analyzed InflaRx NV using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran IFRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Mar 12, 2026•Run Fresh Analysis →

How Risky Is IFRX Stock?

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

Competitive Risk

Medium

Execution Risk

High

Regulatory Risk

Low

What Are the Red Flags for IFRX?

⚠
Failure to secure adequate or favorable financing terms, leading to severe dilution or insolvency
⚠
Continued slow commercial uptake of Gohibic, missing sales targets
⚠
Adverse clinical trial results for pipeline candidates or new indications
⚠
Increased competitive pressure from new or existing treatments for ANCA-associated vasculitis

Unlock IFRX Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does InflaRx NV (IFRX) Do?

Market Cap

$81.30M

Sector

Healthcare

Industry

Biotechnology

Employees

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Visit InflaRx NV Website

Is IFRX Stock Undervalued?

InflaRx (IFRX) remains a highly speculative, high-risk, high-reward biotech play with theoretical 10x potential if critical hurdles are overcome. The EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis offers a strong market opportunity and a unique mechanism of action. However, the company's financial health is critically weak, with an estimated cash runway of 7-10 months remaining from March 2026. Commercialization of Gohibic continues to be slower than required to achieve self-sustainability, making substantial and potentially highly dilutive financing an imminent necessity. While the core product's potential is intact, the probability of overcoming immediate financial challenges and accelerating commercial execution without significant shareholder value erosion remains low, justifying the consistent low score due to persistent financial and operational risks.

Unlock the full AI analysis for IFRX

Get the complete DVR score, risk analysis, and more

Does IFRX Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Stable but vulnerable

Moat Sources

1 Identified

Intangible Assets/IP (patent protection for vilobelimab, regulatory exclusivity from orphan drug designation)

The moat is primarily derived from intellectual property and regulatory exclusivity. Its durability hinges on successful commercialization, further clinical development, and maintaining differentiation against new competitive entrants or alternative therapies. If commercial execution fails, the regulatory and IP moat becomes less valuable.

Moat Erosion Risks

•Failure to effectively commercialize Gohibic, leading to loss of potential market share
•Emergence of superior, more convenient, or more cost-effective treatments for ANCA-associated vasculitis
•Expiration of key patents or orphan drug status without significant market entrenchment

IFRX Competitive Moat Analysis

What Could Drive IFRX Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (Estimated early-mid May 2026), focusing on Gohibic sales and cash position
•Financing announcement (equity, debt, or partnership) - critical and imminent
•Updates on Gohibic commercialization efforts and market penetration in the EU

Medium-Term (6-18 months)

•Sustained acceleration in Gohibic sales and revenue growth in European markets
•Potential strategic partnerships for global commercialization or additional indications
•Progress on vilobelimab's development pipeline or expansion into new therapeutic areas

Long-Term (18+ months)

•Establishment of Gohibic as a leading treatment for ANCA-associated vasculitis globally
•Expansion of vilobelimab's approved indications, broadening the TAM
•Potential acquisition by a larger pharmaceutical company seeking to enhance its rare disease portfolio

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for IFRX?

✓
Significant acceleration in Gohibic sales figures (quarter-over-quarter growth)
✓
Announcement of a favorable financing deal or strategic partnership that significantly extends the cash runway
✓
Positive clinical data for vilobelimab in new indications
✓
Failure to secure financing, continued slow sales, or highly dilutive equity offerings

Bull Case Analysis

See what could go right with Premium

Compare IFRX to Similar Stocks

See how InflaRx NV stacks up against related companies in our head-to-head analysis.

IFRX vs XBI

Compare →

IFRX vs AMGN

Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IFRX (InflaRx NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.